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Nanoparticle-Based Targeting of Vaccine Compounds
to Skin Antigen-Presenting Cells By Hair Follicles and
their Transport in Mice
Brice Mahe1,2,5, Annika Vogt3,5, Christelle Liard1,2, Darragh Duffy1,2, Vale´rie Abadie1,2, Olivia Bonduelle1,2,
Alexandre Boissonnas1,2, Wolfram Sterry3, Bernard Verrier4, Ulrike Blume-Peytavi3 and
Behazine Combadiere1,2
Particle-based drug delivery systems target active compounds to the hair follicle and may result in a better
penetration and higher efficiency of compound uptake by skin resident cells. As previously proposed, such
delivery systems could be important tools for vaccine delivery. In this study, we investigated the penetration of
solid fluorescent 40 or 200 nm polystyrene nanoparticles (NPs) as well as virus particles in murine skin to further
investigate the efficacy of transcutaneously (TC) applied particulate vaccine delivery route. We demonstrated
that 40 and 200 nm NPs and modified vaccinia Ankara (MVA) expressing the green-fluorescent protein
penetrated deeply into hair follicles and were internalized by perifollicular antigen-presenting cells (APCs).
Fibered-based confocal microscopy analyses allowed visualizing in vivo particle penetration along the follicular
duct, diffusion into the surrounding tissue, uptake by APCs and transport to the draining lymph nodes. The
application of small particles, such as ovalbumin coding DNA or MVA, induced both humoral and cellular
immune responses. Furthermore, TC applied MVA induced protection against vaccinia virus challenge. Our
results strengthen the concept of TC targeting of cutaneous APCs by hair follicles and will contribute to the
development of advanced vaccination protocols using NPs or viral vectors.
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INTRODUCTION
Vaccines have generated major successes in the control of
infectious diseases, but several obstacles remain in their
development against pandemic chronic diseases, such as HIV,
hepatitis C or against cancer. Numerous concepts have
successfully been developed in animal models and subse-
quently been brought to clinical trials. The overall outcome,
however, has not met the expectation and is still challenging the
field of immunology and vaccine design. Promising approaches
for innovation include modifications of the mode of vaccine
applications (for example, mucosal, cutaneous), better targeting
of high numbers of antigen-presenting cells (APCs) and
mechanisms of improved antigen processing and presentation.
Among the various approaches, two different strategies
have gained interest during the past years: skin applied
vaccine and nanoparticle (NP) compounds (reviewed in
Combadiere and Mahe, 2008). The great potential of skin
APC targeting is further supported by the finding that the
intradermal injection of one-fifth of the dose of a conven-
tional influenza vaccine is sufficient to induce better or equal
immune responses than conventional intramuscular (IM)
vaccinations (Kenney et al., 2004). Glenn et al. (2000)
elegantly demonstrated that transcutaneous (TC) vaccine
application is safe and efficient. His pioneer studies were
followed within the past few years, by different methods for
TC immunization such as depilation cream (Shi et al., 1999),
abrasion (Guebre-Xabier et al., 2004), or shaving (Glenn
et al., 1998a, b). However, those methods are to some extent
invasive, require the treatment of large skin surfaces and
promote a random penetration through the skin. The small
amount of compound, which passes the horny layer,
penetrates through the layer of keratinocytes, which are
known to be weak immunostimulatory cells (Gaspari and
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Katz, 1988). Keratinocyte uptake decreases the antigenic load
available for the actual immunization. It is thus crucial to
further explore the potential of TC vaccination concepts.
Interestingly, Fan et al. (1999) found that topical vaccination
requires intact hair follicles, pointing to the operation of
efficient mechanisms for induction of immune responses to
proteins encountered within the follicle. Having been
previously identified as a portal for both protein and DNA
entry to the skin (Li and Hoffman, 1995), hair follicles are
candidates for targeted delivery of therapeutic agents (Lauer
et al., 1995).
NP-based vaccine preparations may allow an improved
targeting of APCs in the skin compared to nonparticulate
systems. This hypothesis is supported by former studies,
which suggested that adsorption of vaccine compounds to
NPs trigger the activation of APCs and improve their antigen-
presenting capacity resulting in better immune responses
(Scheicher et al., 1995; Shen et al., 1997; Macklin et al.,
1998). In our previous study on human skin explants
pretreated with cyanoacrylate skin surface stripping (CSSS),
we showed that solid 40 nm NPs penetrated by human hair
follicles into the perifollicular tissue, and we isolated NP-
positive epidermal Langerhans cells (LCs; Vogt et al., 2006).
We used our expertise on particle penetration in human skin
to develop a new vaccine application protocol designed to
target influenza vaccine into human hair follicles. In a pilot
study, we were able to show, that this method was safe and
efficient in the induction of cellular immune responses in
human volunteers (Vogt et al., 2008). Similarly, Yagi et al.
(2006) induced cellular immune responses against HIV and
melanoma peptides in human volunteers using CSSS techni-
que. Both studies emphasize that the optimization of TC
vaccination protocols may allow utilisation of the recently
described function of skin LCs as potent inducers of cellular
immune responses, to develop new immunization systems,
which may be especially valuable for therapeutic vaccination
approaches, for example, immunizations against chronic
viral diseases or cancer (Ueno et al., 2004; Cao et al., 2007).
The aim of this study was to assess the potential of the hair
follicle pathway as a suitable route for vaccine penetration for
NPs, protein, DNA, and virus and its efficacy to generate
protective immune responses. We investigated the percuta-
neous penetration, the cellular uptake and the trafficking of
40 and 200nm solid polystyrene NPs as well as modified
vaccinia Ankara expressing the green-fluorescent protein
(MVA-eGFP) particles in C57Bl6 mice using in vivo fibered-
based confocal microscopy (FCM), fluorescence microscopy
on cryosections and cell separation techniques. The immuno-
genicity of model antigens, including ovalbumin (OVA)
expressing plasmid and MVA-eGFP particles, was assessed
by immune assays to validate our concept of TC targeting of
skin APCs with particle-based vaccines.
RESULTS
Penetration of 40 and 200 nm fluorescent polystyrene particles
in murine hair follicles surrounded by APCs
To determine the size of particles that can penetrate into the
hair follicles, we applied 40 or 200 nm particles on the top of
tape-stripped skin on the flank of C57BL/6 mice. The surface
area of application was 0.50.5 cm2 (Figure 1). The
penetration of both 40 and 200nm NP into the hair follicles
was analyzed on longitudinal 5 mm cryosections of the skin,
where the fluorescent signal of particles was clearly confined
to hair follicle openings (Figure 1, upper panels). Immuno-
fluorescence with anti-CD205 antibodies confirmed that the
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Epidermal CD11c+ sorted cells
40 nm40 nmControl
Control 5 hours 24 hours
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Figure 1. NPs (40 and 200nm) penetrate into the hair follicles that are
surrounded by LCs. (a) Four hours following topical application of 2.51012
fluorescent FITC-NPs (40 and 200nm, indicated by arrows) on tape-stripped
skin flank, analysis of skin cryosections (5 mm thick) revealed aggregation of
NPs in the hair follicle openings and penetration along the follicular duct
(upper panel). Uptake by dermal DCs was confirmed by immunostaining with
anti-CD205 (Texas Red; lower panel). The insert in the lower panel represents
a CD205 expressing DC with its expanded dendrites containing 40 nm FITC-
labeled NPs). Representative sections are shown. Experiments were
performed two times. Bar¼ 42.5mm. (b) In vivo penetration of 40 nm FITC-
NPs on tape-stripped skin flank was studied using fibered confocal laser
scanning microscopy (FCFM). Well-defined signals of fluorescence with a
round shape were obtained at a depth of 80mm (probe HD-1800) from the
skin surface 5 hours after NP application, which correspond to hair follicles.
After 24 hours, the signal became diffuse suggesting translocation of 40 nm
FITC-NPs into the perifollicular tissue (arrows). Bar¼ 14 mm (right and left
panel) and bar¼12 mm (middle panel). (c) To confirm NP uptake by skin
APCs, epidermal sheets of flank skin obtained from mice pretreated with
2.5 1012 fluorescent 40 nm FITC-NPs were separated, and CD11cþ cells
were purified. Microscopic analysis revealed FITC-NPs in CD11cþ CD207
expressing DCs. Bar¼5 mm.
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upper part of the hair follicle is especially rich in skin APCs
such as dermal dendritic cells (DCs; CD205; (Figure 1, lower
panels) and LCs (CD207; data not shown). As shown in
Figure 1 (lower panels), dermal DCs containing FITC-NPs
(Figure 1a, inset) were localized around the hair follicles and
distributed throughout the dermis providing first evidence of
NP penetration into the viable tissue.
In vivo investigation of the distribution of topically applied
NPs on the skin surface became possible by the use of FCM
(Cell-viZio; Mauna Kea Technologies, Paris, France), which
allows for in vivo confocal microscopy at a depth of
80±5 mm from the skin surface. (Figure 1b). The percuta-
neous penetration of fluorescent 40 nm NPs was monitored at
5 and 24 hours after topical NP application and compared to
control mice. At a depth of 80 mm (maximum depth of Cell-
viZio HD-1800 probe) from the skin surface, we found sharp
fluorescent signals with round shape (Figure 1b, middle
panel). At this depth, the signals correspond to hair follicles
filled with fluorescence, that is, they do not reflect surface
distribution of fluorescence on the skin. The sharp border of
those signals corresponds to the epithelium and the fibrous
sheath, which surround the follicular duct. After 24 hours, the
fluorescent signal became more diffuse suggesting a translo-
cation of particles in the perifollicular tissue (Figure 1b, right
panel as indicated by the arrow).
To determine the nature of APCs that were capable to
uptake NPs, we purified CD11cþ cells from the epidermis
3 hours after NPs (40 nm) application. Fluorescent micro-
scopic analysis of individual cells revealed that among
CD207þ cells (80% purified CD11cþ cells from the
epidermis), 36% contained one or more than one fluorescent
particle (Figure 1c, arrows). Our data demonstrate for the first
time under in vivo conditions, that NPs penetrate into open
hair follicles and diffuse into the perifollicular tissue, where
they are taken up by epidermal and dermal DCs.
Trafficking of NPs from skin to DLN but not to non-draining
lymph nodes
To investigate further distribution and trafficking of fluores-
cent NPs after hair follicle penetration, we performed FCM on
skin draining lymph nodes (DLN) compared to non-DLN at 4,
24, and 48 hours after application of fluorescent NP on tape-
stripped skin. As displayed in Figure 2a, FCM showed
aggregations of fluorescent particles as early as 4 hours on
DLN but not in non-DLN. (Figure 2a and b).
We quantified this migration process from the skin to
lymph nodes (LNs) by counting the number of fluorescent
spots per field (three mice, 10 fields per LN per mice).
Average spots per fields are depicted in Figure 2b. In mice
treated with 40 nm particles, the number of fluorescent spots
reached a maximum after 24 hours, whereas no signal was
detectable in non-DLN (Figure 2b). As shown in Figure 2c,
CD11cþ cells purified from DLN contained FITC-NPs.
Fluorescent signals within inguinal LNs of mice treated with
200 nm particles were also clearly detectable, albeit less
frequently than in mice treated with 40 nm particles,
suggesting that the penetration and transport might be less
efficient for 200 nm compared to 40 nm NPs.
Immune response after topical application of ovalbumin DNA
plasmid or protein
To test the capacity of antigenic compounds to generate both
cellular and humoral responses, 100mg of plasmid DNA
encoding for OVA or 100mg of ovalbumin protein (pOVA),
were applied TC on the flank of tape-stripped mice. In the
first set of experiments shown in Figure 3a, we assessed the
T-cell responses after adoptive transfer of carboxyfluorescein
succinimidyl ester (CFSE)-labeled OT-1 CD8 cells from
transgenic mice. We used both CFSE labeling and a congenic
CD45.2 marker to follow in vivo the behavior of transferred
CD8 T cells. Representative dot plots showing CD8þCFSEþ
cells gated on CD8þCD45.2þ cells at day 4 after
vaccination are displayed in Figure 3a. At day 4 after
vaccination, we found the most pronounced increase of
OVA-specific CD8 cell proliferation (less than six divisions as
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Figure 2. FITC (40 and 200nm) NPs applied on tape-stripped mouse skin
reach the proximal draining lymph nodes. (a) Twenty-four hours following
topical application of 2.51012 fluorescent FITC-NPs (40 or 200 nm,
respectively) on tape-stripped skin flank, draining lymph nodes, non-DLN and
spleen were analyzed by fibered confocal fluorescence microscopy (FCFM),
using the surface probe S-1500 (slice thickness of 15 mm and a lateral
resolution of 5 mm). Representative fields are shown for each organ and for
each size of fluorescent beads. Bar¼ 32mm. (b) FITCþ spots were counted in
10 randomly photographed fields (three mice per group, total of 30 fields).
The mean number of FITCþ spots per field in each organ is shown for 40 nm
NPs (left panel) and for 200 nm NPs (right panel) at 4, 24, and 48hours
following application as indicated. Experiments were performed on three
mice, twice. Student’s t-test: *Po0.05, **Po0.01. Bar¼ 32mm. (c) Skin
draining lymph node cells from 10 mice were isolated and purified with
CD11c beads after topical application of 40 nm FITC-NPs on tape-stripped
skin flank. At 24 hours, fluorescent 40 nm particles (arrows) were observed in
CD11cþ cells. Bar¼ 32mm.
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showed by CFSE fluorescent dilution) in DLN proximal
to the vaccination site. Cells that have undergone more
than six divisions were also found in non-DLN (Figure 3a).
These results are in accordance with our previous findings
showing that T-cell priming occurs in the DLNs, where
antigen is mainly presented and cells, after division and
differentiation, migrate to others lymphoid organs (Boissonnas
et al., 2004). This was also shown by low numbers of cells
in division 1–5 in non-DLN compared to the DLNs.
The capacity to induce proliferation was almost nine
times higher for protein than for the DNA, which is in
accordance with their relatively low immunogenicity shown
also after IM immunization (Figure 3b). Overall, both pOVA
and DNA-OVA were immunogenic when topically applied
after tape stripping. Proliferation of OVA-specific CD8 cells
in the LN suggests the transport of the antigen from the skin to
the lymphoid organs.
We also monitored the production of specific IgG
antibodies after TC application of either pOVA or DNA-
OVA by ELISA. In our model, no specific antibodies were
detected at day 14 after TC immunization with pOVA
compared to control, unless a strong adjuvant such as
cholera toxin (CT) was coadministered with the antigen, as
previously demonstrated by Glenn et al. (1998a) (Figure 3c).
DNA plasmid alone, however, induced a humoral response
similar to pOVA with CT (Figure 3c) with no significant
difference between the two groups (P40.05).
In conclusion, after topical application of OVA coding
DNA plasmids or pOVA, cellular immune responses were
observed; however, adjuvants might be necessary for a potent
induction of humoral immune responses.
Skin penetration and immune response after topical application
of modified vaccinia Ankara virus (E290nm)
MVA-eGFP encoded particles, with a size of approximately
290 nm, served as a model for particulate antigen (Gallego-
Gomez et al., 2003). MVA-eGFP encoded fluorescent virus
was used to further investigate the potential of particulate
viruses to penetrate the skin and induce cellular and humoral
immune responses. Detection of TC applied MVA-eGFP
(3107 plaque-forming unit, PFU) in the epidermis was
performed using anti-MVA antibodies (Figure 4). Perifollicu-
lar diffusion of MVA antigen occurred similar to the results
obtained after topical NP application, and we observed the
presence of MVA antigen in perifollicular CD207þ cells
(Figure 4a). Confocal fluorescent microscopy showed that
MVA antigen was detectable particularly in CD207þ cells
expanding their dendrites and surrounding the hair follicle as
shown by Figure 4b.
To track MVA-eGFP, in vivo analysis of fluorescent signal
by FCM was performed and revealed the presence of
fluorescent infected cells or infected cell debris in the DLN
as early as 4 hours after application (Figure 5a). The frequency
of fluorescent spots (Figure 5b) was similar to the one
observed with 200nm particles and less frequent than those
associated with small 40nm NPs (Figure 2). The signal then
significantly decreased at 24 and 48hours after application
suggesting a degradation of the virus. Rapid processing of this
non-propagative virus probably also explains the difficulty to
detect MVA-GFP antigens on cryosections in the DLN.
To test whether MVA penetration by the hair follicle is
immunogenic, we applied MVA (15 106 PFU) on the flank
of the animal after tape stripping (Figure 6). As depicted in
Figure 6a, a marked increase of IFN-g producing CD4 and
CD8 number was observed demonstrating the induction of a
strong cellular response at day 14 after TC immunization. We
also observed that CD4 (both IFN-gþ , IL-2þ ) and CD8
(predominantly IFN-gþ ) responded to the MVA stimulation in
vaccinated animals. Sera of MVA vaccinated animals by TC
route were collected at different time points. As shown in
Figure 6b, at day 28, MVA vaccinated animals produced
significantly higher level of neutralizing Abs than control
group. Mice were then challenged by intranasal route with a
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Figure 3. TC application of OVA encoding DNA or OVA protein promotes
antigen-specific cellular and humoral responses. (a) In vivo OVA-specific
CD8 T-cell proliferation after TC vaccination. CFSE-labeled OT-1 cells from
draining LNs and non-draining LNs were analyzed by flow cytometry. Dot
plots represent CD8þCFSEþ gated on the CD8þCD45.2þ cells at day 4 after
vaccination with 100 mg of OVA DNA plasmid or OVA protein. The
percentages of dividing cells are indicated. Results are representative of three
different experiments. (b) Statistical analysis of the frequency of dividing OT1
cells at day 4 after vaccination with 100mg of OVA DNA plasmid or OVA
protein. Data are representative of three independent experiments. (c)
Induction of IgGs antibodies against ovalbumin after TC vaccination. Mice
were vaccinated with either 100 mg of plasmid DNA coding for ovalbumin
(DNA-OVA; n¼ 8), OVA protein (pOVA; n¼ 6), OVA protein associated with
cholera toxin (pOVAþ cholera toxin; CT¼ 10mg; n¼ 7), or PBS (n¼5). ELISA
was performed on peripheral blood mononuclear cells at day 14 after
vaccination. Results are representative of three different experiments.
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high dose of live vaccinia virus (VV) and monitored for
weight loss (Figure 6c). MVA TC vaccinated animals
presented significantly stable weight compared to unvacci-
nated controls, which developed up to 10% weight loss.
Thus, TC application of MVA was immunogenic and
protective against virus challenge.
DISCUSSION
The results presented in this study reinforce the proof-of-
concept for TC vaccination by demonstrating for the first time
that NPs and particulate model vaccines such as MVA-eGFP
are capable of penetrating murine skin pretreated with tape
stripping. Advanced in vivo and in vitro microscopy
techniques allowed us to identify the hair follicle as a major
penetration pathway. All studied particles (40, 200 nm NP
and MVA-eGFP encoding virus) penetrated along the
follicular duct, translocated into the perifollicular tissue and
were taken up by epidermal and dermal APCs, which
migrated to the proximal LN. We further demonstrated the
capacity of this TC immunization method to generate
immune responses after DNA, protein or virus application.
The data obtained in this experimental murine model are
complementary to our findings obtained on human explants
(Vogt et al., 2006) as well as to our clinical pilot study on TC
application of influenza vaccine (Vogt et al., 2008).
The aggregation and deposition in hair follicle openings is
a key feature of particulate drug preparations, for example,
microspheres, solid and flexible NPs, and liposomes (Lade-
mann et al., 2001, 2007). In fact, Lademann et al. recently
reported retention of 320 nm NPs in hair follicle openings for
up to 10 days in humans using in vivo confocal laser
scanning microscopy, suggesting that topically applied
compounds can be stored in hair follicle openings for
prolonged periods of time providing time for intensive
interactions with the hair follicle epithelium, which, in the
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Figure 4. Modified vaccinia Ankara particles (E290 nm particles) penetrate
into tape-stripped skin and are uptaken by antigen-presenting cells.
Four hours following topical application of MVA-eGFP on tape-stripped skin
flank, skin samples were removed and frozen. Skin cryosections (5 mm thick)
were immunostained with antibodies directed against CD207 (Texas Red)
expressed on Langerhans cells (LCs) and some DDCs (identification of a new
population of langerinþ cells, Bursh, JEM 2007) and anti-MVA (Alexa 488,
green). (a) MVA-eGFP was detected in TC treated skin (right panel, star)
compared to isotype control (left panel). Bar¼ 189mm. (b) Confocal
microscopic analysis ( 63, NA 1.4) of CD207þ cells containing MVA-eGFP
(indicated by arrows). A network of CD207þ cells expressing MVA antigens
can be observed in epidermis and dermis layers surrounding empty follicular
ducts. Bar¼ 51.2 mm (left panel) and bar¼14.2 mm (right panel).
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into the skin and is transported toward the DLN after skin application. (a) At
different time points following TC application of rMVA-eGFP, draining LNs
were analyzed by fibered confocal fluorescence microscopy (FCFM), using
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Bar¼32 mm. (b) Fluorescent spots were counted in 10 randomly
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48hours following application. Student’s t-test: ***Po0.0001. Results are
representative of three different experiments.
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upper part of the hair follicles, is especially rich in APCs
(Christoph et al., 2000).
Although retention of solid particles in the follicular duct
has been well documented, there are only a few reports on the
penetration of solid particles into the viable tissue. In a study
on human skin explants pretreated with CSSS, we recently
demonstrated, that solid NPs with a diameter of 40 nm were
capable of penetrating human skin after CSSS, which induces
mild barrier disruption and opens hair follicles for penetration
(Vogt et al., 2006). We confirmed NP uptake by LCs and
provided first evidence for the fact that translocation of small
NPs into the viable tissue may occur especially in barrier-
disrupted skin. On the basis of these observations we
concluded that NP-based vaccine preparations might allow
improved targeting of APCs in the skin. This hypothesis is
supported by former studies, which suggested that adsorption
of vaccine compounds to NPs trigger the activation of APCs
and improve their antigen-presenting capacity resulting in
better immune responses (Scheicher et al., 1995; Shen et al.,
1997; Macklin et al., 1998). The results presented in this paper
further suggest that small vectors as well as NPs could be used
in TC vaccination strategies.
In this study, we further found that the frequency of 40 nm
particles found in the DLN was slightly higher than the
frequency of 200 nm particles or MVA-eGFP particles
suggesting a difference in NP penetration and uptake. This
finding is consistent with our previous observations in human
skin explants, where the amount and the depth of NP
penetration along the follicular duct strongly depends on the
size of the particles (Toll, Jacobi et al., 2004). In fact, there is
so far little evidence, that NPs at a size exceeding 100 nm
penetrate intact skin (Warheit et al., 2007) and inclusion of
CSSS into TC vaccination protocols, which aims to target NPs
into the viable tissue, is probably crucial. Furthermore,
various studies suggest that stripping techniques may not
only improve NP penetration, but also exert immunostimu-
latory effects. It has been shown that the removal of the
stratum corneum increased expression of MHC class II,
CD86, CD40, CD54, and CD11c on LCs, but did not cause
them to migrate (Nishijima et al., 1997; Takigawa et al.,
2001). Rapid migration from epidermis to DLN was obtained,
however, by exposure to antigen after removal of the stratum
corneum, suggesting that maturation and migration of LCs are
independently regulated events. Indeed, addition of an
adjuvant such as CT increases the immunogenicity of
antigen. Similarly, the use of DNA that can activate
Toll-like receptors can participate to the maturation of APCs
(Dalpke et al., 2002). It has been also shown that the
predominant transfected cell types following intradermal
or IM inoculations of DNA, however, are keratinocytes
after abrasion (Guebre-Xabier et al., 2004). However, the
expression of DNA in LCs and DCs remains unknown
after TC vaccination. Although the evidence for LCs as the
targeted APCs used in topical immunization is indirect, the
observations that immunization can be conducted in
entirely uninflammed skin and that skin hydration has been
involved in this process are highly suggestive that skin
penetration and LC targeting occurs. LCs are a specific
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Figure 6. Modified vaccinia Ankara particles based vaccine induces humoral
and cellular immune responses by TC route. (a) Cytokine production by
MVA-specific CD4 and CD8 T cells. C57BL/6 mice received 15 106 PFU of
MVA, and the CD4 and CD8 T-cell responses in the LN were analyzed on day
14 after application. Lymph nodes were stimulated in vitro with 0.1 PFU of
MVA per cell for 12 hours. Cells surface were stained with anti-CD4 and anti-
CD8, and then cells were stained for intracellular production of IFN-g. The
absolute number of CD4 and CD8 cells producing IFN-g is indicated per LN.
(b) Time course of antibody response to TC application of MVA. Results are
presented for day 28 posttranscutaneous vaccination. Groups of mice (six per
group) received 15106 PFU of MVA or saline buffer as a control. Sera were
collected at different time points following immunization and neutralizing
antibody titers were determined using the neutralization assay that measures
the reduction in infectivity of MVA-eGFP in Hela cells. Results are
representative of three different experiments. Differences between PBS and
TC immunized groups were analyzed using Mann–Whitney test, **Po0.01.
(c) Protective efficacy of TC immunization with MVA in C57BL/6 mice.
Groups of six mice were immunized TC with 5 106 PFU of MVA or saline
buffer as a control. Two months later, mice were challenged intranasally with
5 106 PFU of live vaccinia virus (Copenhagen strain). Individual weight
measured daily is presented as a weight loss percentage for both groups.
Significant difference in weight loss between control group and TC group is
shown, *Po0.05.
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subtype of DCs localized in the epidermis. Functional,
in vitro studies have demonstrated that antigen-pulsed LCs
that have been isolated from epidermis can induce T-cell
proliferation comparable in magnitude to those induced by
similarly pulsed macrophages (Stingl et al., 1978). In
addition, MVA application induced an enhanced immune
response, which was protective.
In summary, we demonstrated that 40 nm fluorescent
polystyrene NPs, after topical application on murine skin,
penetrated by hair follicle openings and translocated into the
viable tissue, where they were internalized by skin APCs.
Moreover, we were able to demonstrate clearly, that within
24 hours, NPs migrated to the proximal LNs, most likely in
association with migrating APCs. Further experiments need to
be performed to study the process of NP internalization by
LCs and DCs and the basis of APC migration and NP
transport. The application of small immunogenic compounds
such as OVA coding DNA or MVA expressing the eGFP
showed that particle-based targeting of hair follicles induced
both humoral and cellular immune responses. TC applied
MVA induced protection against VV challenge. Further
studies using functionalized NPs coated with antigens will
help to validate this route of immunization and its use in
clinical applications; for example, patch applications of
standard vaccines may allow non-invasive large-scale vacci-
nations, vaccination against chronic viral diseases or cancer.
Our data reinforce the concept of TC vaccination with NP-
based vaccines. It is an important and highly promising
approach for future vaccination strategies (see recent review
by our group Combadiere and Mahe, 2008). It takes
advantage of two important particle characteristics: improved
immunogenicity of particle-bound antigens and preferred
penetration by hair follicles, which provide an important
interface for NP interactions with the surrounding tissue and
APCs and subsequent shuttling to lymphoid tissues.
MATERIALS AND METHODS
Mice
Wild-type C57BL/6 females (6–10 weeks of age) were obtained from
Charles River Laboratories (L’arbresle, France). The OT-1 strain is
transgenic for the TCR Va2Vb5 specific for the peptide OVA257–264
(SIINFEKL), expresses the congenic marker CD45.2 and is restricted
to H2-Kb on RAG2/ background. The OT-1 mice were bred, and
all strains were housed at the Nouvelle Animalerie Commune of
Pitie´-Salpeˆtrie`re. All experiments performed at Pitie´-salpe´trie`re
complied with French legislation and ethics committee guidelines
(Departementale des services veterinares).
Antigens
The plasmid vector pVRC2000 used for immunization, coded for the
pOVA and its expression was under a human cytomegalovirus
promoter (Iga, Boissonnas et al., 2007). DNA were produced by
Tebu-Bio (Le Perray en Yveline, France; endotoxin-free,o30EUmg1
of DNA). pOVA (100mgml1) from chicken egg white (Sigma-Aldrich,
St Louis, MO) was diluted in phosphate-buffered saline (PBS) solution
before skin administration. Recombinant MVA-eGFP was kindly
produced by Dr B Verrier originally provided by Transgene Labora-
tories (Strasbourg, France). CT was used as an adjuvant (Sigma, France).
Nanoparticles
For all studies, 40 and 200nm polystyrene particles (FluoreSpheres)
were obtained at Molecular Probes, Eugene, OR (yellow–green
fluorescent, excitation: 505/515 nm, emission: 515 nm). Storage and
handling was performed according to the manufacturer’s recom-
mendations. The FluoSpheres particle NeutrAvidin labeled micro-
sphere were supplied as suspensions (1% solids or, respectively) in
50mM sodium phosphate buffer, 50mM NaCl, pH 7.5, 0.02% Tween
20 and 5mM sodium azide. NPs were diluted as indicated before
usage. Before sampling, sonication was performed for 1minute.
Immunofluorescence on frozen tissue sections or fixed
cell-suspension analysis
Frozen tissues were cryosectioned (5 mm thick) and sections were
fixed for 10minutes in acetone. Slides were sequentially rehydrated
for 10minutes in PBS, treated for 30minutes at room temperature
with PBS–3% BSA or 0.1% saponin/PBS–3% BSA, and incubated for
1 hour at room temperature with purified rat antimouse CD205 (AbD
Serotech, MorphoSys UK Ltd, Oxford, UK) in PBS–BSA 1%, or with
biotin rat antiLangerin/CD207 (Euromedex, Souffelweyersheim (67),
France) in PBS–BSA 1%, 0.1% saponin. Slides were then incubated
1 hour at room temperature with secondary antibody chicken,
respectively, antirat IgG-Alexa fluor 594 or Texas Red-conjugated
streptavidin (Invitrogen, Europe, Paisley, UK). For anti-CD207
staining, before antibody staining, endogenous biotin was blocked
using the avidin/biotin blocking kit (Vector Laboratories, Burlin-
game, CA) for 30minutes at room temperature. After three washes in
PBS, slides were mounted with Fluoromount-G (Southern Biotech-
nology Associates, Birmingham, UK) or Vectashield mounting
medium containing DAPI (Vector Laboratories, UK). Slides were
analyzed with a fluorescence microscope (BX51; Olympus, Rungis,
France) equipped with an image processing and analysis system
Qimaging (Media Cybernetics Inc, Silver Spring, MD). For confocal
microscopy, we used the Leica Sp2 AOBS confocal microscope from
the cell imaging facility of the Pitie´ Salpe´trie`re, all pictures were
taken at  63, NA 1.4.
In vivo confocal microscopy
In vivo penetration of fluorescent NPs was monitored using
noninvasive FCM. The Cell-viZio apparatus (Mauna Kea Technolo-
gies) is a fibered confocal fluorescence microscopy imaging system.
The two optical probes used for acquisition of the images presented
here have respective diameters of 1.5mm (ref. S-1500-5.0) or 1.8mm
(ref. HD-1800-2.5). The S-1500 probe provides images immediately
below the surface of biological tissues, with a slice thickness of 15mm
and a lateral resolution of 5mm. The HD-1800 probe provides images
at 80mm from the surface with a slice thickness of 20mm and a lateral
resolution of 2.5mm. During the time of acquisition, mice were
anesthetized to avoid any movements. The stripped side of each
mouse was wiped with PBS to clean the area prior to acquisition. For
the LN study, the organ was skimmed before the surface analysis with
the probes. Spots were defined as a unitarian signal presenting a high
fluorescent intensity in the center and decreasing levels in the border.
At least 10 different areas per organ for at least three mice (n¼ 30)
were collected and the average numbers of spots per field was
calculated. Measurements were performed at different time points as
indicated. PBS treated mouse tissues were used for background
fluorescence detection.
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Transcutaneous immunization
Mice were anesthetized before TC immunization. In absence of any
mechanical or chemical treatment, tape-stripping procedures using
10 successive adhesive tapes (Lyre´co, France) were applied on the
flank of anesthetized C57BL6 mice to remove all the hair and part of
the stratum corneum before the topical application of vaccine
compounds or NPs as indicated (50ml on 0.25 cm2) in 1 PBS
solution (Gibco, Invitrogen cell culture, Europe, Paisley, UK). For
each striping, a fresh piece of tape was lightly pressed onto the skin
and pulled out. Thus, the surface of treated skin was intact (no
irritation seen). The procedure was standardized to avoid highly
inflamed or damaged skin. If any of these were observed, mice were
excluded from the analysis. Directly after stripping, the solution was
applied and allowed to completely air dry and the mice remained
anesthetized 1 hour during the procedure avoiding external contacts
on the skin. Mice were inspected during the time of experimentation
and we did not observe any change in behavior or excessive
scratching of the skin.
Intramuscular immunization
Mice were immunized by the IM route (in the anterior tibialis) with
50 ml of either saline solution or 100mg of plasmid DNA-OVA needle
with 26G 12 inch, 0.45 12mm needle (Terumo Europe, Leuven,
Belgium) and 1ml seringue (BD Plastipak, Becton Dickinson,
Madrid, Spain).
Immune responses and cell proliferation
OT-1 CD8 cells, specific for the OVA peptide SIINFEKL (257–264),
were isolated from OT-1 transgenic mice LNs, and 4 million CFSE-
labeled cells were adoptively transferred by the intravenous route.
Naive CD8 T lymphocytes were labeled with 5-(and 6)-CFSE (10 mM;
Molecular Probes, Leiden, The Netherlands) as previously described
(Boissonnas, Combadiere et al., 2004). Mice were killed 4 days after
the transfer for collection of the two inguinal LNs (distal and
proximal to the immunized flank) and the spleen. Cell suspensions
were prepared as previously described (Boissonnas, Combadiere
et al., 2004).
ELISPOT assays
gIFN-ELISPOT kit (Diaclone, Strasbourg, France) was used according
to the manufacturer’s instruction. Briefly, freshly isolated cells
(1.0 105 cells) were incubated in triplicates, with or without
MVA (0.1 PFUml1) or concanavalin A (2.5 mgml1). Cells were
incubated during 48 hours at 37 1C. Antigen-specific spot-forming
cell frequencies were measured on an automated microscope (Zeiss,
Munich, Germany) and were counted as positive, if a minimum of
50 spot-forming cell per million peripheral blood mononuclear cells
were detected above background.
ELISA
The ELISA was performed by using two 96-well Immulon plates
(Dynatech Laboratories, Chantilly, VA); each well was coated
overnight at 4 1C with 100 mg of a solution containing either OVA
or hen egg white lysozyme (as a control) per well. Specific anti-OVA
IgG antibodies were detected after incubation with horseradish
peroxidase-conjugated antimouse IgG antibodies (Sigma) diluted in
blocking buffer (10% fetal calf serum in PBS) overnight at 4 1C.
3,3,5,5-Tetramethylbenzidine (Sigma) substrate was added. Twenty
minutes after, the reaction was stopped with H2SO4. Antibody titers
were determined by reading the absorbance at 450 nm.
Intracellular cytokine staining
For intracytoplasmic IFN-g detection, cell suspensions were stimu-
lated overnight with MVA (0.1 PFU per cell) and then incubated for
4 hours at 37 1C with brefeldin A at 5mgml1. The cells were washed
and stained with CD4-FITC or CD8a-PercP. After fixation and
permeabilization with 1 PBS–2% fetal calf serum–0.1% saponin,
cells were stained with APC-conjugated antimouse IFN-g and
phycoerythrin-conjugated anti-IL-2 antibodies. All antibodies were
purchased from BD Biosciences, San Jose, CA. Cells were then run
for four-color fluorescence staining on a cytofluorometer (FACS
Calibur; BD Biosciences) and 50,000 live events per sample were
analyzed with CellQuest software.
Vaccinia virus challenge
Female C57BL/6 mice (6 to 8-week old) were obtained from Charles
River Laboratories, and were housed under specific pathogen-free
conditions. All experiments complied with local animal experimen-
tation and ethic committee guidelines. For protection studies, mice
were immunized with 5 106 PFU of MVA by TC route. Two months
after immunization, mice were challenged intranasally with
5 106 PFU of live VV Copenhagen (generous gift from Transgene
Laboratories), and individual body weight was measured daily.
MVA-eGFP neutralization assay
Neutralizing activities were evaluated using an assay based on flow
cytometric detection of the GFP (Earl et al., 2003; Cosma, Buhler
et al., 2004). This assay used HeLa cells as targets and a recombinant
strain of MVA expressing the enhanced Aequoriae GFP (B Verrier).
The assay was performed in a 96-well round-bottom tissue culture
plate (TPP, Zurich, Switzerland) by adding 2.5 104 PFU of MVA-
eGFP to 40ml of serial dilution of heat-inactivated serum in DMEM
(Gibco, Invitrogen) supplemented with 2% fetal calf serum (PAA,
Laboratories GmbH, Pashing, Austria). The plate was incubated for
1 hour at 37 1C. Then, 1 105 HeLa cells were added in 50ml, and
the incubation was carried out for 16hours in a 37 1C CO2 incubator.
After being washed with PBS supplemented with 0.5% fetal calf
serum and 2mM EDTA, cells were fixed in 2% paraformaldehyde.
GFP expression was analyzed on a total of 10,000 events per sample
using FACSCalibur and CellQuestPro software (BD Biosciences). The
percentage of neutralization was defined as a reduction in the
number of GFP-expressing cells compared to the number of GFP-
expressing cells in untreated control wells. It was calculated as
follows: (1(percentage of GFP-expressing cells/percentage of GFP-
expressing cells in untreated controls)) 100.
Fluorescent microscopic analysis of isolated epidermal APCs
Briefly, 4 hours after tape stripping and NPs application, the tape-
stripped skin from 12 wild-type C57BL/6 females (6–10 weeks of age)
was removed and slightly scratched to eliminate the lipid layer. Skins
were pooled and incubated for 3 hours in Dispase diluted in RPMI
(2.4Uml1) at 37 1C. Dermis was then mechanically separated from
the epidermis. The epidermis layers were incubated for 15minutes in
0.05% trypsin-EDTA (Gibco). Single cell solution was obtained by
mechanical disruption of tissues on 70 mm Nylon cell-strainer filters
(BD Falcon, BD bioscience discovery labware, Redford). The same
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procedure was used for NPs detection in epidermis cells but a
CD11cþ cell sorting was added before be gently dispersed on Poly-
L Lysine coated cover slides (Sigma-Aldrich). Cells were fixed in 2%
paraformaldehyde before immunostainning.
CD11cþ cells sorting
Magnetic CD11cþ cell sorting was performed either on LN or skin
cells using the CD11c MicroBeads (mouse) and the magnetic-
activated cell sorting separation protocol from Miltenyi Biotec,
Bergisch, Gladbach, Germany.
Statistical analysis
We used Prism-4 software for data handling, analysis, and graphic
representation. Statistical significance was set at Po0.05.
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